News

ivWatch Names Kathy Cox as Chief Financial Officer

ivWatch, LLC, inventor of the first and only continuous IV infiltration detection technology, appointments Kathy Cox to Chief Financial Officer. With over 23 years of experience, including 15 years in the medical device manufacturing and healthcare markets, Cox will strengthen the ivWatch leadership team and will provide expertise in driving business growth and operational efficiencies. She will lead the Accounting and Finance functions and report directly to President and Chief Executive Officer Gary Warren.

“Kathy is an exciting addition to our leadership team,” said Gary Warren, President and CEO, ivWatch. “Her strength as a leader at several medical device manufacturers and healthcare companies both privately owned and those held by global publicly-traded parent companies will be invaluable as we continue to grow our company, execute against our long-term strategies, and work to deliver breakthrough technologies to hospitals around the globe.”

“I am thrilled to join ivWatch and work alongside a team of inventors that will continue to improve patient safety and care through relentless innovation,” said Kathy Cox. “The company has a proven track record of putting people first to advance IV therapy and I am excited to bring my knowledge and experience throughout my career to help drive the trajectory of ivWatch and fulfill its mission.”

Prior to joining ivWatch, Cox held a series of executive positions for 12 years within Solesis, an operating division of Michelin and Fenner PLC, including Director/General Manager. She also held the role of Finance Director at Charter Medical and at Xeridiem Medical Devices. Over the course of her career, Cox has developed technical expertise in all aspects of corporate finance, financial planning, and accounting. Her Director/General Manager experience provides her with a strategic business view and commercial mindset that assists in communication of financial data across functional areas of a corporation. She specializes in leading transformative change in teams, processes, and systems to support revenue growth.

Cox, an active CPA since 2000, graduated from Florida State University in Tallahassee, Florida with a B.S. in Accounting.

Recent News

05/14/2025

Civica to start Chesterfield lab construction this summer, eyes Petersburg plant expansion

Nearly three years after announcing plans to build a laboratory in Chesterfield to support its manufacturing operations in Petersburg, Civica Rx is readying plans to kick off the project’s construction. The Utah-based nonprofit drugmaker said it will break ground this summer on a 50,000-square-foot facility at 11731 Meadowville Lane, in the Meadowville Technology Park near Chester.

05/07/2025

Adial Pharmaceuticals raises $2.75M

Glen Allen biopharma company Adial Pharmaceuticals Inc. (NASDAQ: ADIL) has raised $2.75 million from an institutional investor. The company, which specializes in therapies for addiction and related disorders, said it will use the new funding for working capital and general corporate purposes. The name of the investor was not disclosed, but Adial said a “health

05/07/2025

Adovate Granted New U.S. Patent for Therapeutic Uses of A2B Receptor Antagonists

Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting adenosine receptors involved in major diseases, today announced that Patent Number 12,269,828 B2 was issued by the United States Patent and Trademark Office. This newly issued patent covers therapeutic uses of the Company’s lead molecule ADO-5030 and thousands of other novel molecules